-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Reiterates Overweight on Candel Therapeutics, Maintains $15 Price Target

Benzinga·12/08/2025 14:03:36
Listen to the news
Stephens & Co. analyst Sudan Loganathan reiterates Candel Therapeutics (NASDAQ:CADL) with a Overweight and maintains $15 price target.